6 recruiting, 4 completed, 1 unknown. 11 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Recruiting 6, Completed 4, Unknown 1 |
Follow Rescue Medication: new trials by email Literature Review of Rescue Medication trials Research Report on Rescue Medication
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel - Breast Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1000 | 2025-07-21 | 2026-11-03 |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication - Breast Neoplasms, Triple Negative Breast Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 2400 | 2025-06-30 | 2026-10-13 |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) Ifinatamab deruxtecan, Docetaxel, Prednisone - Prostate Cancer, Prostatic Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1440 | 2025-05-13 | 2026-10-30 |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication - Triple Negative Breast Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1000 | 2025-03-16 | 2026-10-13 |
| A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) Zilovertamab vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1046 | 2025-01-27 | 2026-10-21 |
| A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) Sacituzumab tirumotecan, Pembrolizumab, Cisplatin - Non Small Cell Lung Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 780 | 2024-04-03 | 2026-10-15 |
| Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107) asenapine, Placebo to match asenapine, Rescue medication - Bipolar Disorder, Pediatric | Phase 3 | Completed | Organon and Co | 404 | 2011-06-16 | 2024-06-20 |
| Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898) Asenapine, Rescue medication - Bipolar Disorder | Phase 3 | Completed | Organon and Co | 322 | 2011-06-16 | 2024-05-22 |
| Efficacy and Safety Assessment of an Anti-Cold Preparation in the Symptomatic Treatment of Common Cold and Flu-Like Syndrome Resfenol, Placebo, Co interventional acetaminophen - Common Cold, Flu-like Syndrome | Phase 3 | Unknown | Hospital de Clinicas de Porto Alegre | 146 | 2009-06-01 | 2009-07-16 |
| Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011) Telcagepant potassium 150 mg, Telcagepant potassium 300 mg, Zolmitriptan 5 mg - Migraine | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1380 | 2007-02-15 | 2018-10-17 |
| Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097) aprepitant, ondansetron, dexamethasone - Vomiting | Phase 3 | Completed | Merck Sharp & Dohme LLC | 50 | 2004-04-01 | 2014-08-05 |
Bipolar Disorder (2) · Breast Neoplasms (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Triple Negative Breast Neoplasms (2) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Common Cold (1) · Lung Neoplasms (1) · Lymphoma, Large B-Cell, Diffuse (1) · Migraine Disorders (1) · Prostatic Neoplasms (1) · Vomiting (1)
Merck Sharp & Dohme LLC (8) · Organon and Co (2) · Hospital de Clinicas de Porto Alegre (1)
Brazil (7) · Argentina (6) · Australia (6) · Chile (6) · China (6) · France (6) · Greece (6) · Hong Kong (6) · Israel (6) · Italy (6) · Japan (6) · Peru (6) · Poland (6) · South Korea (6) · Spain (6)
PMID 26598478, PMID 21054362, PMID 27461426, PMID 42535874, PMID 42872715
2023 (1), 2025 (1)